



**Box 1. Recommendations for genes to be included for germline-focused analysis and triggering of germline sample laboratory confirmation**

	Any tumour type	Associated tumour type only
Tumour arising any age	<i>BRCA1</i> <i>RAD51C</i> <i>BRCA2</i> <i>RAD51D</i> <i>BRIP1</i> <i>RET</i> <i>MLH1</i> <i>SDHA</i> <i>MSH2</i> <i>SDHAF2</i> <i>MSH6</i> <i>SDHB</i> <i>PALB2</i> <i>SDHC</i> <i>PMS2</i> <i>SDHD</i> <i>VHL</i> <sup>a</sup> <i>TSC2</i> <i>MUTYH</i> <sup>b</sup>	<i>FLCN</i> <i>FH</i> <i>BAP1</i> <i>POLE</i>
Tumour arising age <30 only	<i>RB1</i> <i>APC</i>	<i>TP53</i> <sup>c</sup> <i>NF1</i>

<sup>a</sup>Renal tumours to be excluded.

<sup>b</sup>*MUTYH* should be included for germline-focused tumour analysis but reporting and germline follow-up testing should only be performed on detection of two pathogenic variants.

<sup>c</sup>Brain tumours to be excluded.